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Background. Acting on harmful command hallucinations is a major clinical concern. Our
COMMAND CBT trial approximately halved the rate of harmful compliance (OR = 0.45,
95% CI 0.23–0.88, p = 0.021). The focus of the therapy was a single mechanism, the power
dimension of voice appraisal, was also significantly reduced. We hypothesised that voice
power differential (between voice and voice hearer) was the mediator of the treatment effect.
Methods. The trial sample (n = 197) was used. A logistic regression model predicting 18-
month compliance was used to identify predictors, and an exploratory principal component
analysis (PCA) of baseline variables used as potential predictors (confounders) in their own
right. Stata’s paramed command used to obtain estimates of the direct, indirect and total
effects of treatment.
Results. Voice omnipotence was the best predictor although the PCA identified a highly pre-
dictive cognitive-affective dimension comprising: voices’ power, childhood trauma, depression
and self-harm. In the mediation analysis, the indirect effect of treatment was fully explained by
its effect on the hypothesised mediator: voice power differential.
Conclusion. Voice power and treatment allocation were the best predictors of harmful com-
pliance up to 18 months; post-treatment, voice power differential measured at nine months
was the mediator of the effect of treatment on compliance at 18 months.
Acting on delusions and commanding voices, remains a major concern for psychiatry with
attendant societal and political concern, where members of the public are subject to apparently
random acts of violence, even when they are well supported by services. Harm to self is an even
greater risk linked to commanding voices (Birchwood et al. 2014). This is reflected in national
policy documents, for example, the national mental health strategy in England aimed to reduce
‘avoidable harm’ to self or others (UK Department of Health, 2011).. While drug treatment has
improved, approaching 50% will continue to experience treatment-resistant symptoms or
symptoms arising from non-adherence to drug regimes (Leucht et al. 2009). Auditory hallu-
cinations (AH) rank among the most prominent of the treatment-resistant symptoms and
among the most distressing and high risks of all are command hallucinations (Upthegrove
et al. 2016). Command hallucinations are prevalent in people with schizophrenia and related
disorders. A review by Shawyer et al. (2003) reported a median prevalence rate of 53% with a
wide range from 18% to 89%, in a sample of adult psychiatric patients; of these, 48% stipulated
harmful or dangerous actions. Among patients in medium secure units, compliance rises to
69% (Rogers et al. 2002). This rate appears significantly higher in the forensic population
with 83% of voice hearers experiencing command hallucinations with criminal content
(Beck-Sander et al. 1997). However, the link between the presence of command hallucinations
and harm to self or others is not straightforward. In the Macarthur study (Appelbaum et al.
2000), no association was reported between the presence of delusions or command hallucina-
tions and violence (GBH, assault and threats with a weapon). It appears to be the content of
the individual’s thinking and how this reflects the dynamics of their relationship with the sup-
posed persecutor who is commanding them, that is found to be predictive of harm to self and
others (Beck-Sander et al. 1997; Bucci et al. 2013). Our cognitive model of ‘voices’ has clarified
that it is not only the level of activity of voices, or indeed their content, that drives affect and
behaviour, but the nature of the relationship with the personified voice (Chadwick &
Birchwood, 1994; Birchwood et al. 2004; Connor & Birchwood, 2013); see review by
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Mawson et al. (2010). We showed that where the voice hearer
believes the voice to have malevolent intent, and crucially to
have the power to deliver the threat, this can motivate compliance
or appeasement behaviour (Birchwood et al. 2004). These find-
ings have been independently replicated in a forensic population
(Fox et al. 2004). This framework informed the development of
our targeted cognitive behaviour therapy (CBT) treatment
designed to weaken and challenge a single mechanism, beliefs
about voices’ power, thus enabling the individual to break free
of the need to comply or appease and thereby reduce harmful
compliance behaviour and distress (Byrne et al. 2006; Meaden
et al. 2013). The effect of cognitive therapy for command halluci-
nations (CTCH) was tested in a full multi-centre trial of 197 indi-
viduals with a recent history of harmful compliance, involving
harm to themselves or others. This group was observed to have
a 46% rate of recurrence of harmful compliance within 18 months
in the control group compared with 28% of those receiving CTCH
[odds ratio = 0.45, 95% confidence interval (CI) 0.23–0.88, p =
0.021]. This was accompanied by a reduction in the perceived
power of the voice (the estimated treatment effect common to
both time points was −0.52 [95% CI −0.849 to −0.185), p =
0.002]. No differential impact on other secondary outcomes was
observed.
In our main results paper (Birchwood et al. 2014) we high-
lighted two outstanding questions from our protocol
(Birchwood et al. 2011), of theoretical and clinical importance.
First, what are the key baseline predictors of outcome at 18
months? Here we are interested in whether it is voice beliefs,
psychosis severity, demographic and historical factors, treatment
allocation, or a combination of these, which predict further acts
of harmful compliance; our preliminary study found voice
power to be the best individual predictor (Bucci et al. 2013).
Second, while these results were in line with predictions (changes
in power and in compliance) we did not establish voice power as
the mediator of change, as predicted by our model. This paper
addresses each of these questions.
Method
Trial design
This was a single (rater) blind, prospective, pragmatic randomised
controlled trial, using intention to treat comparing CTCH +
Treatment as usual (TAU) with TAU alone. The trial recruited eli-
gible participants from UK sites in Birmingham, Leicester,
London and Manchester.
The trial was funded by the Medical Research Council
(G0500965), was registered (ISRCTN62304114) and received eth-
ical approval from the West Midlands Research Ethics Committee
(06/MRE07/71). Full details on the design and trial findings can
be found in the trial protocol (Birchwood et al. 2011) and primary
publication (Birchwood et al. 2014).
Participants
A total of 197 of 242 eligible participants consented to the trial
(81%), fulfilling the following criteria: (i) ICD – 10 schizophrenia,
schizoaffective (F20, 22, 23, 25, 28, 29), or mood disorders (F32)
(WHO, 2009), under care of a clinical team; (ii) age ⩾16; (iii) his-
tory of command hallucinations of at least 6 months with recent
(<9 months) history of harm to self, others or major social trans-
gressions as a result of the commands; or harmful command
hallucinations where the individual is distressed and appeasing
the powerful voice and therefore at risk of full compliance.
Exclusion criteria included: organic impairment or addictive dis-
order considered to be the primary diagnosis; insufficient com-
mand of the English language. The mean age of the sample was
37.4 (12.1; 16–64) and 113 (57%) male. Harmful compliance
included harm to self (n = 119), others (42), kill self and/or
other (53). All were in receipt of anti-psychotic medication.
The intervention and treatment as usual
CTCH is designed to weaken and change beliefs about voices’
power, thus enabling the individual to break free of the need to
comply or appease and thereby reduce harmful compliance
behaviour and distress. Our CTCH treatment protocol was devel-
oped by the first author and detailed in our casebook manuals
(Byrne et al. 2006; Meaden et al. 2013). The primary aim of the
therapy is to reduce the power differential between voice and
voice hearer. The essence of the therapy is to test out the perceived
power of the voice by examining evidence for: (a) the voice
hearer’s perceived lack of control over voice activity, (b) the per-
ceived omniscience of the voice (e.g. the apparent ability of the
voice to predict the future) and (c) the perceived capacity of the
voice to carry out its threats for non-compliance. CTCH was
administered over a maximum period of 9 months. This includes
a therapeutic window up to 25 sessions. TAU was provided by
Community Mental Health Teams, Assertive Outreach and
Early Intervention Teams. TAU including anti-psychotic medica-
tion was documented and did not differ between the groups.
Measures
Compliance
The level of compliance/resistance was assessed using the Voice
Compliance Scale (VCS) (Addington et al. 1993) after: (a) con-
ducting a thorough interview using the Cognitive Assessment of
Voices schedule in order to obtain a detailed record of all voices
as well as emotional and behavioural responses towards these
voices; (b) interviewing and using information from at least one
other informant (carers, care-coordinator). This yields specific
behaviours which are classified as: neither appeasement nor com-
pliant (1); symbolic appeasement, i.e. compliant with innocuous
and/or harmless commands (2); actual appeasement, i.e. prepara-
tory acts or gestures (3); partial compliance with at least one
severe command (4); full compliance with at least one severe com-
mand (5). Twenty-nine of these were independently rated by MM
for the presence v. absence of full compliance, with an overall
Kappa of 0.73.
The primary outcome was the presence of full compliance
(score 5) over the preceding nine months, with documented
and independently verified behaviours. This was accordingly trea-
ted as a binary measure in the regression analyses.
Beliefs about voices
Power
The Voice Power Differential Scale (VPD-total) (Birchwood et al.
2004) was used to measure the perceived power differential
between voice and voice hearer, which includes the following con-
structs: power, strength, confidence, respect, ability to inflict
harm, superiority and knowledge. This scale has good internal
reliability (Cronbach’s α = 0.85) with high 1-week re-test
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reliability (r = 0.82). The first item on the scale, the ‘pure’ power
differential between voice and voice hearer, was analysed separ-
ately in keeping with our protocol and full trial. This item like
the others in the scale is a bipolar construct on a five point
scale (‘In relation to my voice I feel much more powerful….much
less powerful’) and will be referred to as VPD-power.
Omniscience
The Personal Knowledge questionnaire/Omniscience scale
(Birchwood et al. 2004) measured the voice hearer’s beliefs
about the voice’s knowledge regarding personal information
(e.g. ‘The voice knows everything about me and my past’).
Voices’ intentions
The Beliefs about Voices Questionnaire-Revised (BAVQ-R)
(Chadwick et al. 2000) was used to assess key beliefs about voices’
omnipotence and intentions, whether benevolent or malevolent,
as well as participants’ emotional and behavioural reactions
towards their voices (resistance v. engagement). The scale has
good test-retest (r = 0.89) and internal reliability (Cronbach’s α
= 0.85) and is widely used in hallucinations research.
Auditory hallucinations
Voices were assessed using the Psychotic Symptoms Rating Scales
(PSYRATS) (Haddock et al. 1999) and specifically the section
about AH. The scale benefits from excellent psychometric proper-
ties with inter-rater reliability for the AH section ranging between
0.78 and 1.0.
Depression, hopelessness & suicidal ideation
The Calgary Depression Rating Scale for Schizophrenia
(Addington et al. 1993) is a widely used nine-item observer-rated
measure specifically designed for schizophrenia, minimising con-
tamination by negative symptoms and the extrapyramidal side
effects of neuroleptics. The Beck Hopelessness Scale (Beck,
1988) was used to assess three aspects of hopelessness: feelings
about the future, loss of motivation and expectations and the
Beck Scale for Suicidal Ideation allows for a thorough examination
of suicidal intent.
Psychotic symptoms
The Positive and Negative Syndrome Scale (PANSS) (Kay et al.
1987) includes scales of positive symptoms, negative symptoms
and general psychopathology and is used widely in schizophrenia
research.
Childhood neglect and trauma
The Childhood Trauma Questionnaire (Bernstein and Fink, 1988)
is a widely used 28-item self-report inventory measuring retro-
spectively experiences of childhood abuse and neglect. It consists
of five subscales: emotional abuse, physical abuse, sexual abuse,
emotional neglect and physical neglect, reflecting, therefore, a
broad range of early adverse experiences. The CTQ has proved
to have high internal reliability with α-value ranging from 0.66
for the physical abuse subscale to 0.92 for the sexual abuse sub-
scale. It has also demonstrated good test–retest reliability ranging
from 0.79 to 0.86 for the five subscales over an average period of
four months.
Statistical methods
Baseline predictors of 18-month compliance
All statistical analyses were carried out using Stata version 13 (Stata
Corporation, 2013). Thirty pre-randomisation, baseline predictor
variables were considered including voice beliefs (13 variables),
psychosis severity (four variables), parental abuse and neglect
(five variables), demographic and historical factors (five variables)
and effective functioning (three variables) in addition to treatment
allocation and centre membership. In order to avoid confusion,
readers should note that psychologists’ term ‘predictive variable’
does not have the same meaning as ‘predictive marker’ as used in
the personalised medicine literature (Dunn et al. 2013). The latter
is equivalent to the psychologists’ ‘moderator’ (a treatment effect
modifier). Here, we are dealing with potential predictors that are
assumed to have the same effect in both arms of the trial. The start-
ing point (as in the initially reported evaluation of treatment effi-
cacy (Birchwood et al. 2014) was a logistic regression model to
predict 18-month full compliance by treatment allocation, centre
membership (two binary dummy variables, C1 and C2) and base-
line compliance on the VCS (with three levels). Centre member-
ship was kept in all of the statistical models because of the trial
design: randomisation taking place within (or stratified by) centre.
Baseline compliance was not a statistically-significant predictor
and was then dropped from the model. So, starting with a model
containing the effects of treatment and centre membership, each
of the 30 potential predictors were added in turn, and their predict-
ive effects and associated statistical significance assessed using
the likelihood ratio-based chi-square statistics. The effects of
employment and marital status were not assessed since there was
too little variation in these measures. The best (most statistically
significant) predictor was kept in a new baseline model and each
of the remaining 29 potential predictors again added in turn, and
their predictive ability determined. This forward selection proced-
ure was accompanied by a corresponding backward elimination,
starting with a model with all potential predictors and proceeding
until deletion of a potential predictor led to a statistically significant
worsening in goodness-of-fit (again, indicated by the change in
chi-square).
As a result of the above analyses, a selection of the potential
predictors was made, based on their ability to predict outcome
over and above treatment and centre membership. These baseline
predictors were likely to be fairly highly correlated and their cor-
relation matrix was then subjected to an exploratory principal
components analysis, and the principal components extracted
and saved to be used as potential predictors in their own right.
Mediation analysis
Here, again, all initial statistical analyses were carried out using
Stata version 13 (StataCorp, 2013). The analyses are aimed at evalu-
ating the potential mediating role of voice power (VPD) (either the
total score or the power differential item) in the treatment effect on
compliance at 18 months. The main potential threat to the validity
of the findings is confounding of the effect of the mediator (VPD)
on outcome (Compliance), even though the treatment itself has
been randomised. Another threat (or source of bias) is measure-
ment error in the putative mediator. First, we concentrated on
adjustment for confounding. The logistic regression model for
the outcome (18-month compliance) initially included the effects
of treatment and the following covariates: centre membership
(two binary dummy variables, C1 and C2) the first principal
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component score (PCA1) obtained from the above analysis of
potential predictors (defined in the ’Results’ section). This pro-
duced a revised intention-to-treat effect. PCA1 was included
because it is likely to be an important confounder of the effect of
the putative mediator on the clinical outcome – being a powerful
predictor of both the VPD scores and 18-month compliance.
Linear regression models for the putative mediator (VPD-total
score at 9 months or the VPD-power item) included the effects
of treatment and the same set of covariates. Finally, the second
pair of logistic regression models for 18-month compliance was fit-
ted, containing the same variables as the first ones above but, with
the addition of the putative mediators: the 9-month values for
either the VPD total score or the VPD power item. The latter mod-
els were also fitted using Stata’s paramed command (Emsley et al.
2014; Dunn et al. 2015): in order to obtain estimates of the direct,
indirect and total effects of treatment. Standard errors and 95% CI
were used via the use of bias-corrected bootstrap methods (each
based on 1000 bootstrapped samples) – see (Efron and
Tibshirani, 1993). Readers should be aware that the total effects
of treatment will not correspond exactly to the estimate reported
in the original trial report (Birchwood et al. 2014). Hence, the
phrase ‘revised intention-to-treat effect’ as used above. This is not
a sign of disagreement but follows from the fact that treatment
effects are being estimated using odds ratios, conditional on the
other covariates in the model. As the additional covariates change
so does the definition of the treatment effect (unlike the case when
using linear regression/ANCOVA models for quantitative
outcomes).
Finally, we evaluated mediation models in which 9- and
18-month measurements of the VPD-total score (or the
VPD-power item) were assumed to be replicate measurements
of an underlying latent variable (factor – labelled VPD-Total in
the case of the total score, and VPD-Power for the power item).
The latent factor was used to address measurement error. The
replicate measurements for each of the two factors were assumed
to have zero relative bias and the same measurement error var-
iances (precision – i.e. they were assumed to be parallel mea-
sures). We would, of course, expect the precision of the power
item to be considerably lower than that for the total score. This
simple factor analysis model was then fitted simultaneously
with a logistic regression model to predict 18-month compliance
using the structural equations program Mplus version 7.0
(Muthen and Muthen, 2012). The covariates in the latter were
treatment, centre membership (C1 and C2), PCA1 and the
VPD factor as the putative mediator (either the VPDT or VPDP).
Results
Intention to treat analysis
The evaluation of the primary outcome was through an
intention-to-treat (ITT) analysis using a logistic regression, allow-
ing for centre membership and severity of command hallucinations
at baseline. This is detailed in our primary publication (1) but in
summary, 197 participants (see Table 1) were randomly assigned
(98 to CTCH + TAU and 99 to TAU), representing 81.4% of eligible
individuals. At 18 months, 46% of the TAU participants fully
complied compared to 28% of those receiving CTCH + TAU
(odds ratio = 0.45, 95%CI 0.23–0.88, p = 0.021). A summary of out-
come and mediator measures over time by randomisation group is
shown in Table 2. The estimate of the treatment effect common to
both follow-up points was an odds ratio of 0.57 (95% CI 0.33–0.98,
p = 0.042); that for 18-month compliance was an odds ratio of 0·45,
95%CI 0.23–0.88, p = 0·021. The total estimated treatment effect for
VPD-total common to both time points was −1.819 (95%
CI −3.457 to −0.181, p = 0.03). For the VPD-power differential
item, the estimated treatment effect for both time-points was –
0.52 (–0.849 to –0.185, p = 0.002).
Baseline predictors of 18-month compliance
In addition to the effect of treatment there were also centre differ-
ences in 18-month compliance; however, once other baseline pre-
dictors were added to the model these centre effects were very
variable. When each of the potential predictors (Table 3) were
added to the logistic model, one at a time, 11 were found to
have a statistically-significant effect, using the uncorrected nom-
inal significance level of 0.05. The results are shown in Table 4,
ranked according to their associated p value. The best predictor
was BAVQ Omnipotence with stronger beliefs linked to compli-
ance ( p = 0.005). When the latter was kept in the model and
the other potential predictors were then added, one at a time,
the only one to significantly add to the prediction was CTQ emo-
tional abuse ( p = 0.045). Bearing in mind the repeated testing or
multiplicity problem (i.e. family-wise error rates), the latter is
almost certainly of no consequence. A backwards elimination
confirmed the above results, yielding a model that contained
treatment, centre and BAVQ Omnipotence.
In a further set of analyses, a principal component analysis was
carried out on the correlation matrix for the eleven statistically
significant predictors in Table 4. The first four principal compo-
nents had eigenvalues of 3.690, 1.652, 1.137 and 1.034, respect-
ively (explaining 68% of the total variation). Returning to the
predictive models, the only principal component to predict
18-month compliance was the first one (which was essentially
the average, after standardisation, of the eleven selected baseline
variables). The estimated odds ratio for an increase of one unit
of the 1st principal component was 1.503 (S.E. 0.165; p value
<0.001; 95% CI 1.211–1.865). The estimated odds ratio for the
treatment effect in this model was 0.476 (S.E. 0.179; p value
0.048; 95% CI 0.228–0.993). Manchester had lower levels of
18-month compliance than Birmingham/Leicester (odds ratio
0.329; S.E. 0.156; p value 0.019; 95% CI 0.130–0.834), as did
London (odds ratio 0.300; S.E. 0.135; p value 0.008; 95% CI
0.124–0.727). There was no suggestion that the treatment effect
was in anyway moderated by the level of the baseline first
Table 1. Description of COMMAND trial sample at baseline
Total (%)
Gender (male): 113 (57%)
Site: Birmingham/Leicester 87 (44%)
Manchester 48 (24%)
London 62 (31%)
Ethnicity: non-white 68 (35%)
Employment: Employed 16 (32%)
Unemployed 144 (74%)
Other 19 (10%)
Cohabiting: yes 20 (10%)
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principal component (i.e. the 1st principal component by treat-
ment interaction had a p value of 0.915).
The eleven baseline predictor variables given equal weight in
the PCA 1st principal component were: BAVQ Omnipotence
and Malevolence scales, CTQ Physical abuse and Emotional
abuse scales, CDSS (Depression), VPD Voice power (total), BSI
(Suicidal thinking) PSYRATS voices (total), CTQ Emotional neg-
lect, PKQ (Omniscience) and PANSS Positive total. These encom-
pass beliefs about voices power and threat; childhood trauma;
depression and self-harm all of which have featured as key
Table 2. Summary of outcome and mediator measures over time by randomisation group
Baseline 9 months 18 months
Full compliance CTCH 84 (86%) 41 (48%) 22 (28%)
TAU 81 (81%) 49 (55%) 39 (46%)
VPD power: mean (S.D.) CTCH 3.9 (1.2) n = 97 2.8 (1.2) n = 87 2.8 (1.3) n = 76
TAU 4.0 (1.0) n = 98 3.3 (1.4) n = 86 3.2 (1.4) n = 81
VPD total: mean (S.D.) CTCH 26.5 (5.5) n = 95 21.3 (5.9) n = 87 22.4 (6.2) n = 75
TAU 27.4 (4.6) n = 96 24.0 (6.4) n = 85 23.4 (6.9) n = 81
VPD, Voice power differential; CTCH, Cognitive therapy for command hallucinations; TAU, Treatment as usual.
Table 3. Baseline predictors: summary statistics
Variable Observed Mean S.D. Min Max
Age at onset 178 22.140 10.562 5 63
PANSS Positive 197 19.381 4.865 10 33
PANSS Negative 195 16.021 6.293 7 34
PANSS General 195 36.374 8.602 17 71
PANSS Total 195 71.733 16.559 38 132
CDSS (Depression) 197 12.091 6.008 0 27
BHS (Hopelessness) 193 10.720 5.395 1 20
BSI (Suicidal thinking) 196 9.908 9.372 0 34
PKQ (Omniscience) 197 10.594 3.218 1 15
VPD (Voice power) 195 3.923 1.103 1 5
VPD total 191 26.953 5.054 9 35
PSYRATS total 194 32.629 4.400 18 41
BAVQ Malevolence 197 13.051 4.332 2 18
BAVQ Benevolence 196 3.367 3.989 0 15
BAVQ Omnipotence 197 13.487 3.748 0 18
BAVQ Resistance (total) 197 21.381 4.856 5 27
BAVQ Resistance (E) 197 9.853 2.302 1 12
BAVQ Resistance (B) 197 11.528 3.599 0 15
BAVQ Engagement (total) 197 5.061 4.919 0 21
BAVQ Engagement (E) 197 1.990 2.837 0 12
BAVQ Engagement (B) 197 3.071 2.874 0 12
CTQ (Emotional abuse) 192 14.135 6.677 5 25
CTQ (Physical abuse) 190 10.484 5.818 5 25
CTQ (Sexual abuse) 190 10.326 7.411 5 25
CTQ_(Emotional neglect) 192 12.995 6.437 5 25
CTQ (Physical neglect) 192 9.547 4.845 5 25
VPD, Voice power differential; BAVQ, Beliefs about voices questionaire; CTQ, Childhood trauma questionaire; PANSS, Positive and negative syndrome scale; BSI, Beck suicide inventory; BHS,
Beck hopelessness scale; CDSS, Calgary depression scale for schizophrenia; PKQ, Personal knowledge questionaire; PSYRATS, Psychosis rating scales.
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features of our cognitive model of voices. We interpret this com-
ponent therefore as the cognitive-affective dimension of the
experience of hearing voices.
Mediation analysis
It is hypothesised that CTCH will give the patient more power
over the voice and the ability to resist its commands and so
make them less likely to comply. The power differential between
the voice and the patient was measured by the VPD total. The
power item is a 1–5 rating where a score of one indicates power
with the individual and 5 indicates that the power lies with the
voice. An improvement would therefore be indicated by a reduc-
tion in the total VPD-total and VPD-power items. We are
hypothesising that VPD power at 9 months mediates the impact
of treatment on compliance at 18 months. These hypotheses are
supported by the results provided below.
Results of fitting predictive models for 18-month compliance,
and for 9-month VPD-total and VPD-power scores, are given in
Table 5a–c. These simply confirm the original ITT analyses. Note
that both centre membership and PCA1 are included in all models
evaluating the effect of the mediator on outcome. The next step
involves the inclusion of the putative mediators in the outcome
model. These results are given in Table 5d and e. In Table 5d, it
can be seen that the effect of the proposed mediator is highly stat-
istically significant (although the estimated odds ratio is very close
to unity, it should be remembered that this is the effect of increasing
the 9-month VPD total by a single unit). The effect of treatment not
explained by the 9-month VPD-total has an estimate (odds ratio
0.526) that is closer to the null than that given in Table 5a, again
consistent with the hypothesis of mediation by the 9-month
VPD-total measure. However the estimate of this direct effect is
very imprecise (see 95% CI) and not very informative. The corre-
sponding analysis, evaluating the possible mediating effect of
9-month VPD-power item indicates that there is little evidence of
mediation by this measure (see Table 5e). We present what we
believe is a more interpretable statistic in the following paragraph.
Stata’s paramed was used to estimate the direct and indirect
effects of treatment, based on the same models for the putative
mediator and final outcome as described above. Here, paramed
produces three estimates: the total effect of treatment, the natural
indirect effect of treatment and the natural direct effect of treat-
ment, together with their 95% CI. The total effect (te) is equiva-
lent to the above ITT estimate. The natural indirect effect (nie) is
defined as the effect on 18-month compliance of changing the
value of the mediator (VPD) from that which it would have
had in the control condition to that which it has under treatment,
whilst setting Treatment = 1 (i.e. everyone receives the interven-
tion). The corresponding natural direct effect (nde) is the effect
of receiving treatment (changing Treatment from 0 to 1) whilst
fixing the mediator at the value it would have had under the con-
trol condition (Treatment = 0). Using 9-month VPD total as the
mediator, we obtain the following estimates: te = 0.402 (95% CI
0.153–0.998); nie = 0.763 (95% CI 0.456–0.939); nde = 0.526
(95% CI 0.215–1.503). Using 9-month VPD power we obtain:
te = 0.410 (95% CI 0.166–1.107); nie = 0.889 (95% CI 0.603–
1.005); nde = 0.461 (95% CI 0.191–1.193). Note that the estimated
direct effects are exactly the same as those reported in Table 5d
and e, respectively, but with wider confidence intervals. The esti-
mated natural indirect effects (both odds ratios less than unity)
correspond to that component of the treatment effect that is
fully explained by its effect on the mediator. We conclude that
9-month VPD total is a mediator of the effect of treatment on
18-month compliance, but it is difficult to establish whether all
of the treatment effects is explained by it (the fact that the corre-
sponding direct effect is not significantly different from unity
does not mean that it actually is unity – we cannot rule out
lower values). The estimated natural indirect effect for 9-month
VPD power, however, is not statistically significantly different
from unity (the 95% CI straddles the value of 1) and conclude
that we have not been able to demonstrate that VPD power is a
mediator.
Finally, the latent variable model evaluating the mediating
effect of VPD-total factor led to an estimated effect of the medi-
ator on the outcome of 1.113 (95% CI 0.995–1.245), consistent
with the estimate in Table 5d, but less precise. Measurement
error does not appear to be a major source of bias, here. The cor-
responding result for the VPD power factor was 1.381 (95% CI
0.829–2.303). Again, measurement error does not appear to be
a major source of bias, but the estimates are so imprecise that
we stick with the conclusion that we have not been able to dem-
onstrate that VPD power is a mediator of the treatment effect.
Discussion
The COMMAND trial tested the effectiveness of our targeted
CBT to reduce the risk of harmful compliance with commanding
voices in those who had complied within the previous nine
months. The trial showed a large and significant reduction in
both the compliance and the central target of the therapy, beliefs
about the power of voices, in particular, the difference in power
between voice and voice hearer. In this paper, we addressed two
central and related questions that are at the heart of the cognitive
model and the CBT: to what degree does voice power and
omnipotence predict compliance at final follow-up and did it
act as the mediator of change? The logistical regression procedure
identified eleven baseline predictors of outcome, over and above
treatment and centre membership. The stepwise elimination rou-
tine identified BAVQ voice omnipotence as the best individual
predictor; the other baseline predictors did not seem to have
any predictive ability not explained by BAVQ omnipotence.
Table 4. Significant individual predictors of 18-month compliance
Predictor Odds ratio S.E. p value 95% CI
BAVQ Omnipotence 1.163 0.063 0.005 1.046 1.292
BAVQ Malevolence 1.122 0.051 0.011 1.027 1.226
CTQ (Physical abuse) 1.076 0.032 0.013 1.015 1.139
CTQ (Emotional abuse) 1.071 0.030 0.014 1.014 1.131
CDSS (Depression) 1.074 0.032 0.015 1.014 1.138
VPD Voice power (total) 1.099 0.043 0.017 1.017 1.188
BSI (Suicidal thinking) 1.046 0.020 0.018 1.008 1.085
PSYRATS (voices) total 1.105 0.047 0.019 1.017 1.201
CTQ_(Emotional neglect) 1.065 0.030 0.024 1.008 1.125
PKQ (Omniscience) 1.141 0.066 0.024 1.018 1.279
PANNS Positive 1.074 0.038 0.044 1.002 1.151
VPD, Voice power differential; BAVQ, Beliefs about voices questionaire; CTQ, Childhood
trauma questionaire; PANSS, Positive and negative syndrome scale; BSI, Beck suicide
inventory; CDSS, Calgary depression scale for schizophrenia; PKQ, Personal knowledge
questionaire; PSYRATS, Psychosis rating scales.
6 Max Birchwood et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291717003488
Downloaded from https://www.cambridge.org/core. University of Birmingham, on 11 Jan 2018 at 11:03:05, subject to the Cambridge Core terms of use, available at
These baseline predictors were however highly correlated and
their correlation matrix was then subjected to an exploratory prin-
cipal components analysis; the principal components extracted
were saved to be used as potential predictors in their own right.
The eleven predictors loaded equally on the first principal compo-
nent, comprising beliefs about voices power and threat; childhood
trauma; depression, hopelessness and suicidal thinking all of
which are the key features of our cognitive model of voices. We
describe this as the cognitive-affective dimension of voice hearing
and it is this that strongly predicted 18-month compliance. In
testing the mediating effect of voice power differential, the first
principal component was an important variable to include as a
confounder in the mediation model, confirmed by its highly sig-
nificant prediction of 9-month compliance.
In the subsequent mediation analysis, controlling for any con-
founding effect of centre and PCA1, we found that the estimated
natural indirect effects of treatment corresponded to that component
of the treatment effect that is fully explained by its effect on the
hypothesised mediator: 9-month voice power differential. There
were no direct effects of treatment once the effect on the mediator
was accounted for. We conclude that 9-month VPD-total was a
mediator of the effect of treatment on 18-month compliance.
While we cannot rule out a direct effect of treatment on outcome,
it is very difficult to obtain a precise estimate of this residual (unme-
diated) treatment effect; if there were comparable trials it would be
an ideal candidate for an IPD (individual patient data) meta-analysis.
We have been able to demonstrate the mediating role of
VPD-total, but have failed to demonstrate the same for VPD
Table 5. Revised intention-to-treat (ITT) estimates, together with the effects of proposed mediators.
(a) 18-month compliance: ITT
Covariate Odds ratio p-value 95% CI
Treatment 0.476 0.048 0.228–0.993
C1 0.329 0.019 0.130–0.834
C2 0.300 0.008 0.124–0.727
PCA1 1.503 <0.001 1.212–1.865
(b) 9-month VPD total: ITT
Covariate Coef. p-value 95% CI
Treatment −2.884 0.002 −4.720 to −1.048
C1 −2.040 0.079 −4.321 to 0.241
C2 −0.349 0.755 −2.552 to 1.855
PCA1 0.999 <0.001 0.505–1.493
(c) 9-month VPD power: ITT
Covariate Coef. p-value 95% CI
Treatment −0.545 0.006 −0.933 to −0.157
C1 −0.409 0.096 −0.891 to 0.073
C2 −0.143 0.544 −0.609 to 0.322
PCA1 0.131 0.014 0.027–0.236
(d) 18-month compliance with 9-month VPD total as a mediator
Covariate Odds ratio p-value 95% CI
Treatment 0.526 0.116 0.236–1.173
9-m VPD total 1.098 0.009 1.023–1.179
C1 0.278 0.012 0.102–0.752
C2 0.213 0.002 0.080–0.571
PCA1 1.457 0.002 1.146–1.852
(e) 18-month compliance with 9-month VPD power as a mediator
Covariate Odds ratio p-value 95% CI
Treatment 0.461 0.054 0.210–1.012
9-m VPD power 1.242 0.178 0.906–1.701
C1 0.260 0.007 0.097–0.698
C2 0.224 0.002 0.086–0.583
PCA1 1.524 <0.001 1.210–1.921
PCA1, Principal component 1; VPD, Voice power differential.
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power item. This may be a sample size (statistical power) problem
arising from a measure that contains considerable error variance.
We cannot rule out a direct effect of treatment on outcome, and it
is very difficult to obtain a precise estimate of this residual (unme-
diated) treatment effect.
Strengths and limitations
This trial mediation analysis has many strengths that lend confi-
dence to the findings. This was a carefully designed and imple-
mented RCT specifically targeted on voice power to achieve
change in compliance with command hallucinations, and with a
corresponding a priori hypothesis that voice power was the medi-
ator. We employed a large sample size of a complex and difficult
to recruit group, with a high rate of follow-up in both groups
(83%). We made a careful search and allowance for predictors
that could be used for confounder adjustment in the mediation
models. Similarly, a careful check was made for the sensitivity
of the results to measurement errors in the mediators. The predic-
tion analysis was based on a prior hypothesis based on our cog-
nitive model and on evidence from a preliminary study showing
that voice power was the principal predictor of 9-month compli-
ance (Bucci et al. 2013).
There are some caveats. First, although the data support the
view that the effect of treatment on compliance is mediated by
voice power differential (VPD-total) there is insufficient power
to confidently rule out any possibility of some effect of treatment
not mediated in this way (i.e. we cannot exclude a direct effect of
treatment, including non-specific on compliance). Second, the
trial did not find a differential impact of treatment on distress
linked to voices (distress declined in both groups). Our previous
cross-sectional and prospective work had led us to predict a treat-
ment effect on voice-related distress, but this was not found,
meaning we were unable to conduct a mediation analysis on
this variable (though distress was a secondary outcome). Finally,
there may be other methods of enhancing the power of the
voice hearer: ‘avatar therapy’ (Leff et al. 2013) is rooted in our
cognitive model and uses facsimile of voices to develop control
and enhance power; similarly ‘relating’ therapy (Hayward et al.
2016) involves the rehearsal of assertive approaches to relating
to the voice and to another significant problematic relationship.
We can conclude that the treatment effect in this trial was
mediated by voice power but we cannot rule out the influence
of other, for example, non-specific effects of the therapy, that
could account for its impact.
Implications
This trial mediation analysis brings to full circle our influential
cognitive model we formulated over 20 years ago (Chadwick &
Birchwood, 1994). We argue that it provides convincing evidence
that in relation to harmful behaviour at least, the perceived power
of voices to threaten the individual, relative to the perceived power
of the individual to challenge and mitigate this threat (power dif-
ferential), is a strong and malleable influence on voice-related
behaviour. Had the mediation analysis not supported the role of
voice power, this would have questioned the foundation of the
therapy in its focus on voice power differential and raised ques-
tions about other active agents, for example, demand characteris-
tics of the trial, a placebo effect or bias. On the contrary, the
mediation analysis supports the clinical model and opens the
door for further research to understand the development of
these appraisals as an interpersonal phenomenon and to explore
the clinical model and its applicability to the generality of dis-
tressed voice hearers and to other symptoms where these apprai-
sals are active, particularly persecutory delusions. Research is
needed to augment this approach with methods to further reduce
distress; in our structural equation model of voice distress
(Birchwood et al. 2004) we identified that generalised subordin-
ation to others and depression appeared to be powerful drivers
of distress in the relationship with voices and these may be targets
for intervention for lasting change in voice distress. For the clin-
ician working with individuals with harmful voices, assessment
should include the perceived power of the voice relative to the
individual, the sources of voice power and those of the voice
hearer. We have documented the majority of cases (Byrne et al.
2006; Meaden et al. 2013) in the trial and pilot for the interested
clinician. We have argued (Birchwood, 2015) that the next gener-
ation of CBTp should focus not on complex packages of care,
where the mechanisms are unclear and the ability of the interven-
tion to modify them is lost in the scattershot; rather we offer this
paradigm of theoretical development, leading to targeted inter-
vention focused on the mechanism of interest, as the path most
likely to maximise clinical effectiveness of the next generation
of cognitive therapy for psychosis.
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